{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:08:47Z","timestamp":1790104127975,"version":"4.0.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01041-2","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:28:43Z","timestamp":1780410523000},"page":"789-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dermatologic Adverse Events Associated with T-Cell Engager Therapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Mihir K.","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod E.","family":"Nambudiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-1549","authenticated-orcid":false,"given":"Connie R.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"4","key":"1041_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell J, Lammers PE, Djuretic I, et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther. 2019;106(4):781\u201391. https:\/\/doi.org\/10.1002\/cpt.1396.","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"1041_CR2","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton MR, McAlpine C, Woodcock VK, et al. A TCR\/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma. Clin Cancer Res. 2020;26(22):5869\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1247.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1041_CR3","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nm.2764","volume":"18","author":"N Liddy","year":"2012","unstructured":"Liddy N, Bossi G, Adams KJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012;18(6):980\u20137. https:\/\/doi.org\/10.1038\/nm.2764.","journal-title":"Nat Med"},{"issue":"9","key":"1041_CR4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","volume":"133","author":"G Albayrak","year":"2025","unstructured":"Albayrak G, Wan PKT, Fisher K, Seymour LW. T cell engagers: expanding horizons in oncology and beyond. Br J Cancer. 2025;133(9):1241\u20139. https:\/\/doi.org\/10.1038\/s41416-025-03125-y.","journal-title":"Br J Cancer"},{"issue":"7","key":"1041_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14740338.2025.2470875","volume":"24","author":"X Le","year":"2025","unstructured":"Le X, Zhang Y, Ma J. Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database. Expert Opin Drug Saf. 2025;24(7):821\u201330. https:\/\/doi.org\/10.1080\/14740338.2025.2470875.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1041_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol. 2004;122(3):565\u201373. https:\/\/doi.org\/10.1046\/j.0022-202X.2004.12628.x.","journal-title":"J Invest Dermatol"},{"key":"1041_CR7","doi-asserted-by":"publisher","unstructured":"Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179(3):1005\u20139. https:\/\/doi.org\/10.1084\/jem.179.3.1005.","DOI":"10.1084\/jem.179.3.1005"},{"issue":"10396","key":"1041_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(23)00521-4.","journal-title":"Lancet"},{"key":"1041_CR9","unstructured":"US FDA. FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma. January 26, 2022. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma. [Accessed 16 Jun 2025]."},{"key":"1041_CR10","unstructured":"European Medicines Agency. Kimmtrak. April 22, 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kimmtrak. [Accessed 10 Jul 2025]."},{"issue":"24","key":"1041_CR11","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2304753.","journal-title":"N Engl J Med"},{"issue":"11","key":"1041_CR12","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","volume":"28","author":"RD Carvajal","year":"2022","unstructured":"Carvajal RD, Butler MO, Shoushtari AN, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med. 2022;28(11):2364\u201373. https:\/\/doi.org\/10.1038\/s41591-022-02015-7.","journal-title":"Nat Med"},{"key":"1041_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.020","author":"GJ Riew","year":"2025","unstructured":"Riew GJ, Hijaz BA, Haq R, Chen ST, LeBoeuf NR, Shi CR. Severity and progression of dermatologic adverse events associated with tebentafusp: a retrospective multicenter cohort study. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.020.","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"1041_CR14","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1200\/JCO.21.01805","volume":"40","author":"RD Carvajal","year":"2022","unstructured":"Carvajal RD, Nathan P, Sacco JJ, et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol. 2022;40(17):1939\u201348. https:\/\/doi.org\/10.1200\/JCO.21.01805.","journal-title":"J Clin Oncol"},{"key":"1041_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112986","volume":"191","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Berking C, Forschner A, et al. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp. Eur J Cancer. 2023;191:112986. https:\/\/doi.org\/10.1016\/j.ejca.2023.112986.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1041_CR16","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1111\/ajd.13866","volume":"63","author":"JP Pham","year":"2022","unstructured":"Pham JP, Star P, Ardolino L, Smith A, Joshua AM. A review of the cutaneous toxicities of tebentafusp: featuring two cases involving superficial bullous reactions. Australas J Dermatol. 2022;63(3):e279\u201382. https:\/\/doi.org\/10.1111\/ajd.13866.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"1041_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/ced\/llad387","volume":"49","author":"I Rodriguez","year":"2024","unstructured":"Rodriguez I, Norman T, Guenther J, et al. Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights. Clin Exp Dermatol. 2024;49(4):392\u20134. https:\/\/doi.org\/10.1093\/ced\/llad387.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1041_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jid.2024.03.048","volume":"145","author":"JC Hassel","year":"2025","unstructured":"Hassel JC, Stanhope S, Greenshields-Watson A, et al. Tebentafusp induces a T-cell-driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J Invest Dermatol. 2025;145(3):559-72.e9. https:\/\/doi.org\/10.1016\/j.jid.2024.03.048.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1041_CR19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaad.2024.08.037","volume":"91","author":"D Tomsitz","year":"2024","unstructured":"Tomsitz D, Kerl K, French LE, Heinzerling L. Clinical and pathological characterization of tebentafusp-associated skin toxicity: a cohort study with 33 patients. J Am Acad Dermatol. 2024;91(6):1136\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2024.08.037.","journal-title":"J Am Acad Dermatol"},{"key":"1041_CR20","doi-asserted-by":"publisher","DOI":"10.5070\/D329662993","author":"LM Fahmy","year":"2023","unstructured":"Fahmy LM, Schreidah CM, McDonnell DE, Carvajal RD, Magro CM, Geskin LJ. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatol Online J. 2023. https:\/\/doi.org\/10.5070\/D329662993.","journal-title":"Dermatol Online J"},{"key":"1041_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01464-y","volume":"16","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, Reck M, Johnson ML, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66. https:\/\/doi.org\/10.1186\/s13045-023-01464-y.","journal-title":"J Hematol Oncol"},{"key":"1041_CR22","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. May 16, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer. [Accessed 14 Jul 2025]."},{"key":"1041_CR23","unstructured":"European Medicines Agency. EU\/3\/23\/2876: orphan designation for treatment of small cell lung cancer. April 11, 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-23-2876. [Accessed 14 Jul 2025]."},{"issue":"16","key":"1041_CR24","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;41(16):2893\u2013903. https:\/\/doi.org\/10.1200\/JCO.22.02823.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1041_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104538","volume":"10","author":"AC Chiang","year":"2025","unstructured":"Chiang AC, Olmedo Garcia ME, Carlisle JW, et al. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open. 2025;10(4):104538. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104538.","journal-title":"ESMO Open"},{"issue":"4","key":"1041_CR26","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s12325-025-03136-4","volume":"42","author":"HD Hummel","year":"2025","unstructured":"Hummel HD, Ahn MJ, Blackhall F, et al. Patient-reported outcomes for patients with previously treated small cell lung cancer receiving tarlatamab: results from the DeLLphi-301 phase 2 trial. Adv Ther. 2025;42(4):1950\u201364. https:\/\/doi.org\/10.1007\/s12325-025-03136-4.","journal-title":"Adv Ther"},{"issue":"22","key":"1041_CR27","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"issue":"18","key":"1041_CR28","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0612.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1041_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","volume":"17","author":"JD Ransohoff","year":"2017","unstructured":"Ransohoff JD, Kwong BY. Cutaneous adverse events of targeted therapies for hematolymphoid malignancies. Clin Lymphoma Myeloma Leuk. 2017;17(12):834\u201351. https:\/\/doi.org\/10.1016\/j.clml.2017.07.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1041_CR30","unstructured":"US Food and Drug Administration. FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell. [Accessed 18 Aug 2025]."},{"issue":"9","key":"1041_CR31","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1080\/10428194.2023.2221756","volume":"64","author":"R Parisi","year":"2023","unstructured":"Parisi R, Cowen EA, Gu S, et al. Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab. Leuk Lymphoma. 2023;64(9):1583\u20137. https:\/\/doi.org\/10.1080\/10428194.2023.2221756.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1041_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jdcr.2017.01.017","volume":"3","author":"MM Liau","year":"2017","unstructured":"Liau MM, Long V, Huang J, Jaffar H. Blinatumomab-associated vasculitis. JAAD Case Rep. 2017;3(5):395\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2017.01.017.","journal-title":"JAAD Case Rep"},{"issue":"2","key":"1041_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000479575","volume":"4","author":"D Paurobally","year":"2018","unstructured":"Paurobally D, Andre J, Richert B. Nail pyogenic granuloma following treatment with blinatumomab. Skin Appendage Disord. 2018;4(2):96\u20137. https:\/\/doi.org\/10.1159\/000479575.","journal-title":"Skin Appendage Disord"},{"issue":"8","key":"1041_CR34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(22)00335-7.","journal-title":"Lancet Oncol"},{"key":"1041_CR35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205046","volume":"144","author":"L Falchi","year":"2024","unstructured":"Falchi L, Okwali M, Ferreira Lopes A, et al. Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: primary analysis of the Mithic-FL1 trial. Blood. 2024;144:340. https:\/\/doi.org\/10.1182\/blood-2024-205046.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1041_CR36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202085","volume":"144","author":"DA Russler-Germain","year":"2024","unstructured":"Russler-Germain DA, Wan F, King ER, et al. Mosunetuzumab plus polatuzumab vedotin induces early complete responses in previously untreated high tumor burden follicular lymphoma. Blood. 2024;144(Suppl. 1):4414. https:\/\/doi.org\/10.1182\/blood-2024-202085.","journal-title":"Blood"},{"issue":"2","key":"1041_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.23736\/S2784-8671.25.08061-2","volume":"160","author":"C Zengarini","year":"2025","unstructured":"Zengarini C, Mussi M, Robuffo S, et al. Epcoritamab injection site skin eruption: a frequent yet unharmful effect due to a local delayed reaction mechanism. Ital J Dermatol Venereol. 2025;160(2):185\u20136. https:\/\/doi.org\/10.23736\/S2784-8671.25.08061-2.","journal-title":"Ital J Dermatol Venereol"},{"issue":"4","key":"1041_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12185-024-03833-w","volume":"120","author":"O Imataki","year":"2024","unstructured":"Imataki O, Uemura M, Fujita H, Kadowaki N. Pathological landscape of tumor flare reaction to epcoritamab treatment. Int J Hematol. 2024;120(4):467\u201371. https:\/\/doi.org\/10.1007\/s12185-024-03833-w.","journal-title":"Int J Hematol"},{"issue":"2 Suppl.","key":"1041_CR39","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.jtct.2023.12.200","volume":"30","author":"W Bahaj","year":"2024","unstructured":"Bahaj W, Hegazi M, Emmons R. Unveiling immediate pseudo-progression with epcoritamab in lymphoma treatment: case series exploration. Transplant Cell Ther. 2024;30(2 Suppl.):S157. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.200.","journal-title":"Transplant Cell Ther."},{"issue":"24","key":"1041_CR40","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"key":"1041_CR41","unstructured":"European Medicines Agency. Columvi. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/columvi. [Accessed 18 Aug 2025]."},{"key":"1041_CR42","unstructured":"Columvi\u00ae (glofitamab-gxbm) side effects. Available from: https:\/\/www.columvi-hcp.com\/safety\/summary.html. [Accessed 27 Apr 2026]."},{"key":"1041_CR43","doi-asserted-by":"publisher","unstructured":"Denosumab\/glofitamab\/obinutuzumab. React Wkly. 2025;2070(1):193. https:\/\/doi.org\/10.1007\/s40278-025-87261-4.","DOI":"10.1007\/s40278-025-87261-4"},{"issue":"Suppl. 1","key":"1041_CR44","doi-asserted-by":"publisher","first-page":"6540","DOI":"10.1182\/blood-2024-202904","volume":"144","author":"J Yang","year":"2024","unstructured":"Yang J, Wang L. Rapid step-up dosing schedule of glofitamab is feasible for relapsed\/refractory diffuse large B cell lymphoma patients. Blood. 2024;144(Suppl. 1):6540. https:\/\/doi.org\/10.1182\/blood-2024-202904.","journal-title":"Blood"},{"issue":"2","key":"1041_CR45","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1210\/en.2011-1504","volume":"153","author":"VI Alexaki","year":"2012","unstructured":"Alexaki VI, Pelekanou V, Notas G, et al. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies. Endocrinology. 2012;153(2):739\u201349. https:\/\/doi.org\/10.1210\/en.2011-1504.","journal-title":"Endocrinology"},{"issue":"6","key":"1041_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"issue":"3","key":"1041_CR47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","volume":"31","author":"A Seckinger","year":"2017","unstructured":"Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396\u2013410. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.002.","journal-title":"Cancer Cell"},{"key":"1041_CR48","unstructured":"US Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. [Accessed 12 Jul 2025]."},{"key":"1041_CR49","unstructured":"European Medicines Agency. Tecvayli. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecvayli. [Accessed 12 Jul 2025]."},{"key":"1041_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jdcr.2024.10.013","volume":"56","author":"IC Yoon","year":"2024","unstructured":"Yoon IC, Do N, Vazquez T, Elder DE, Steele KT, Rosenbach M. Injection site reaction to teclistamab in a patient with multiple myeloma. JAAD Case Rep. 2024;56:48\u201350. https:\/\/doi.org\/10.1016\/j.jdcr.2024.10.013.","journal-title":"JAAD Case Rep."},{"issue":"1","key":"1041_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ajh.70130","volume":"101","author":"MB Hammami","year":"2026","unstructured":"Hammami MB, Haney SP, DeAvila D, et al. Dermatologic adverse effects with elranatamab mimicking talquetamab. Am J Hematol. 2026;101(1):218\u201321. https:\/\/doi.org\/10.1002\/ajh.70130.","journal-title":"Am J Hematol"},{"issue":"9","key":"1041_CR52","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"1041_CR53","unstructured":"Mohty M, Iida S,  Bahlis NJ, et al. Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (rrmm): MAGNETISMM-3. Available from: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420996\/mohamad.mohty.long-term.survival.after.elranatamab.monotherapy.in.patients.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Delranatamab. Accessed 3 Sep 2025."},{"issue":"5","key":"1041_CR54","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40259-025-00735-z","volume":"39","author":"T Shastri","year":"2025","unstructured":"Shastri T, Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies in hematologic malignancies: attacking the frontline. BioDrugs. 2025;39(5):793\u2013814. https:\/\/doi.org\/10.1007\/s40259-025-00735-z.","journal-title":"BioDrugs"},{"issue":"22","key":"1041_CR55","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(22):2702\u201312. https:\/\/doi.org\/10.1200\/JCO.24.01008.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1041_CR56","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, et al. A T-cell\u2013redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343. https:\/\/doi.org\/10.1182\/blood.2019003342.","journal-title":"Blood"},{"issue":"485","key":"1041_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746. https:\/\/doi.org\/10.1126\/scitranslmed.aau7746.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1041_CR58","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A, Krishnan A, Rasche L, et al. Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk. 2024;24(10):665-93.e14. https:\/\/doi.org\/10.1016\/j.clml.2024.05.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1041_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03991-5","author":"S Iida","year":"2025","unstructured":"Iida S, Sunami K, Ito S, et al. Phase 1 study of talquetamab, a humanized GPRC5D \u00d7 CD3 bispecific antibody, in Japanese patients with relapsed\/refractory MM. Int J Hematol. 2025. https:\/\/doi.org\/10.1007\/s12185-025-03991-5. (Epub 9 May).","journal-title":"Int J Hematol"},{"key":"1041_CR60","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma. 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma. [Accessed 10 Jul 2025]."},{"key":"1041_CR61","unstructured":"European Medicines Agency. Talvey. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/talvey. [Accessed 10 Jul 2025]."},{"key":"1041_CR62","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CMAR.S441550","volume":"17","author":"KC Miller","year":"2025","unstructured":"Miller KC, Hamadeh I, Tan CR. Perspectives on talquetamab and its utility in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res. 2025;17:743\u201356. https:\/\/doi.org\/10.2147\/CMAR.S441550.","journal-title":"Cancer Manag Res"},{"issue":"16_Suppl.","key":"1041_CR63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_Suppl.):8036. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8036.","journal-title":"J Clin Oncol"},{"key":"1041_CR64","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/s2152-2650(24)02001-9","volume":"24","author":"JC Ye","year":"2024","unstructured":"Ye JC, Schinke C, Touzeau C, et al. P-098 Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:S99. https:\/\/doi.org\/10.1016\/s2152-2650(24)02001-9.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"1041_CR65","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"issue":"2","key":"1041_CR66","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","volume":"90","author":"M Lery","year":"2024","unstructured":"Lery M, Perrot A, Ortiz-Brugu\u00e9s A, et al. Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab. J Am Acad Dermatol. 2024;90(2):376\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.094.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1041_CR67","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/ddg.15502","volume":"22","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Mart\u00edn-Torregrosa D, Mart\u00ednez-Cozar V, Arnao-Herraiz M, Botella-Estrada R. Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review. J Dtsch Dermatol Ges. 2024;22(9):1282\u20136. https:\/\/doi.org\/10.1111\/ddg.15502.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"1041_CR68","doi-asserted-by":"publisher","first-page":"828","DOI":"10.36849\/jdd.7170","volume":"22","author":"M Kresch","year":"2023","unstructured":"Kresch M, Guenin S, Mubasher A, Elbogen E, Lebwohl M. Talquetamab-induced Grover\u2019s disease. J Drugs Dermatol. 2023;22(8):828\u20139. https:\/\/doi.org\/10.36849\/jdd.7170.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1041_CR69","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1159\/000538047","volume":"147","author":"AD Heini","year":"2024","unstructured":"Heini AD, Bacher VU, Akhoundova D, Seipel K, Pabst T. Peeling back the layers: recurrent talquetamab skin toxicity after supportive stem cell boost in multiple myeloma. Acta Haematol. 2024;147(6):729\u201334. https:\/\/doi.org\/10.1159\/000538047.","journal-title":"Acta Haematol"},{"issue":"7","key":"1041_CR70","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.3324\/haematol.2023.284436","volume":"109","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Beltran S, Goldfinger M, et al. Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma. Haematologica. 2024;109(7):2368\u201371. https:\/\/doi.org\/10.3324\/haematol.2023.284436.","journal-title":"Haematologica"},{"issue":"4","key":"1041_CR71","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 2025;12(4):e269\u201381. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5.","journal-title":"Lancet Haematol."},{"issue":"6","key":"1041_CR72","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","volume":"19","author":"D Pan","year":"2024","unstructured":"Pan D, Richter J. Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma. Curr Hematol Malig Rep. 2024;19(6):237\u201345. https:\/\/doi.org\/10.1007\/s11899-024-00740-z.","journal-title":"Curr Hematol Malig Rep"},{"key":"1041_CR73","doi-asserted-by":"publisher","unstructured":"Quigley C, Qassabi AMA, Murphy L, et al. BH17 A case of talquetamab-induced onychomadesis with associated palmoplantar keratoderma and desquamation. Br J Dermatol. 2024;191(1):i80. https:\/\/doi.org\/10.1093\/bjd\/ljae090.164.","DOI":"10.1093\/bjd\/ljae090.164"},{"key":"1041_CR74","doi-asserted-by":"publisher","unstructured":"Sandahl T, Rattu MA, Jiang G, et al. Management of patients with relapsed\/refractory multiple myeloma treated with talquetamab: highlights from pharmacists\u2019 perspectives. J Adv Pract Oncol. Epub 6 May 2025. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.15.","DOI":"10.6004\/jadpro.2025.16.7.15"},{"key":"1041_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/lary.32445","author":"GM Kayahara","year":"2025","unstructured":"Kayahara GM, Espinhosa RB, da Silva SN, et al. Talquetamab-induced dysgeusia successfully treated with photobiomodulation therapy. Laryngoscope. 2025. https:\/\/doi.org\/10.1002\/lary.32445.","journal-title":"Laryngoscope"},{"key":"1041_CR76","doi-asserted-by":"publisher","unstructured":"Popat R, Laheij A, van de Donk NWCJ, et al. Prophylactic interventions for oral toxicities with the GPRC5D\u00d7CD3 bispecific antibody talquetamab in relapsed\/refractory multiple myeloma: an update on the open-label, phase 2, randomized TALISMAN study. J Clin Oncol. Epub 1 Jun 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS7565.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7565"},{"issue":"1","key":"1041_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08233-0","volume":"32","author":"AMGA Laheij","year":"2023","unstructured":"Laheij AMGA, van de Donk NWCJ. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Support Care Cancer. 2023;32(1):20. https:\/\/doi.org\/10.1007\/s00520-023-08233-0.","journal-title":"Support Care Cancer"},{"issue":"14","key":"1041_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35927","volume":"131","author":"C Schinke","year":"2025","unstructured":"Schinke C, Touzeau C, Oriol A, et al. Talquetamab improves patient\u2010reported symptoms and health\u2010related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL\u20101 study. Cancer. 2025;131(14):e35927. https:\/\/doi.org\/10.1002\/cncr.35927.","journal-title":"Cancer"},{"issue":"4","key":"1041_CR79","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jha2.971","volume":"5","author":"S Naqvi","year":"2024","unstructured":"Naqvi S, Shrestha A, Alzubi M, et al. Weight loss and dysgeusia in relapsed\/refractory multiple myeloma patients treated with talquetamab. eJHaem. 2024;5(4):789\u201392. https:\/\/doi.org\/10.1002\/jha2.971.","journal-title":"eJHaem"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01041-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:21:48Z","timestamp":1784186508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01041-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1041"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01041-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No funding was received for the preparation of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicole R. LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, Janssen, Astellas, Fortress Biotech, and Synox Therapeutics outside the scope of the submitted work. Mihir K. Patil, Brigette Wang, Vinod E. Nambudiri, and Connie R. Shi have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for the publication of recognizable patient photographs or other identifiable material was obtained where applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CRS conceived the review topic and supervised the project. The literature search, screening, and data extraction and synthesis were performed by MKP and BW, with oversight from CRS, VEN, and NRLeB. Figure conception and curation were led by MKP (Fig.\n                      \n                      created in BioRender) with input from CRS; MKP and BW drafted the initial manuscript and tables. All authors contributed to critical revision of the manuscript for vital inclusion of scholarly content and approved the final version of the article.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}